X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Torrent Pharma with GSK Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

TORRENT PHARMA vs GSK PHARMA - Comparison Results

TORRENT PHARMA    Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

GSK PHARMA 
   Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    TORRENT PHARMA GSK PHARMA TORRENT PHARMA/
GSK PHARMA
 
P/E (TTM) x 38.4 53.6 71.6% View Chart
P/BV x 6.8 10.6 63.7% View Chart
Dividend Yield % 0.8 2.7 27.9%  

Financials

 TORRENT PHARMA   GSK PHARMA
EQUITY SHARE DATA
    TORRENT PHARMA
Mar-18
GSK PHARMA
Mar-18
TORRENT PHARMA/
GSK PHARMA
5-Yr Chart
Click to enlarge
High Rs1,5502,760 56.2%   
Low Rs1,1442,040 56.1%   
Sales per share (Unadj.) Rs354.7339.0 104.6%  
Earnings per share (Unadj.) Rs40.141.4 96.8%  
Cash flow per share (Unadj.) Rs64.245.9 139.9%  
Dividends per share (Unadj.) Rs14.0035.00 40.0%  
Dividend yield (eoy) %1.01.5 71.3%  
Book value per share (Unadj.) Rs273.1242.9 112.5%  
Shares outstanding (eoy) m169.2284.70 199.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.87.1 53.6%   
Avg P/E ratio x33.657.9 58.0%  
P/CF ratio (eoy) x21.052.3 40.1%  
Price / Book Value ratio x4.99.9 49.9%  
Dividend payout %34.984.5 41.3%   
Avg Mkt Cap Rs m227,897203,280 112.1%   
No. of employees `00014.7NA-   
Total wages/salary Rs m11,3535,234 216.9%   
Avg. sales/employee Rs Th4,083.0NM-  
Avg. wages/employee Rs Th772.3NM-  
Avg. net profit/employee Rs Th461.3NM-  
INCOME DATA
Net Sales Rs m60,02128,715 209.0%  
Other income Rs m2,988545 547.9%   
Total revenues Rs m63,00929,260 215.3%   
Gross profit Rs m13,4935,059 266.7%  
Depreciation Rs m4,086380 1,075.3%   
Interest Rs m3,0852 154,240.0%   
Profit before tax Rs m9,3105,222 178.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0178 0.0%   
Tax Rs m2,5291,892 133.7%   
Profit after tax Rs m6,7813,508 193.3%  
Gross profit margin %22.517.6 127.6%  
Effective tax rate %27.236.2 75.0%   
Net profit margin %11.312.2 92.5%  
BALANCE SHEET DATA
Current assets Rs m52,62321,815 241.2%   
Current liabilities Rs m52,02215,999 325.2%   
Net working cap to sales %1.020.3 4.9%  
Current ratio x1.01.4 74.2%  
Inventory Days Days12064 188.1%  
Debtors Days Days7619 407.9%  
Net fixed assets Rs m85,01612,475 681.5%   
Share capital Rs m846847 99.9%   
"Free" reserves Rs m45,37619,726 230.0%   
Net worth Rs m46,22220,573 224.7%   
Long term debt Rs m41,1156 685,243.3%   
Total assets Rs m142,43239,475 360.8%  
Interest coverage x4.02,612.0 0.2%   
Debt to equity ratio x0.90 305,000.7%  
Sales to assets ratio x0.40.7 57.9%   
Return on assets %6.98.9 77.9%  
Return on equity %14.717.1 86.0%  
Return on capital %14.226.2 54.1%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m14,580564 2,585.1%   
Fx outflow Rs m3,6007,429 48.5%   
Net fx Rs m10,980-6,865 -159.9%   
CASH FLOW
From Operations Rs m8,9424,728 189.1%  
From Investments Rs m-47,070-1,042 4,517.7%  
From Financial Activity Rs m34,174-3,066 -1,114.5%  
Net Cashflow Rs m-3,655620 -589.8%  

Share Holding

Indian Promoters % 71.5 0.0 -  
Foreign collaborators % 0.0 50.7 -  
Indian inst/Mut Fund % 7.0 10.2 68.8%  
FIIs % 12.6 23.8 52.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.8 15.4 57.1%  
Shareholders   26,511 102,036 26.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare TORRENT PHARMA With:   PANACEA BIOTECH  DISHMAN PHARMA  J.B.CHEMICALS  NATCO PHARMA  DIVIS LABORATORIES  

Compare TORRENT PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Marginally Higher; Realty and Energy Stocks Witness Buying(Closing)

Indian share markets witnessed volatility during closing hours and ended their day marginally higher. Gains were largely seen in the realty sector.

Related Views on News

GSK PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 26.0% (Quarterly Result Update)

Feb 5, 2019 | Updated on Feb 5, 2019

For the quarter ended December 2018, GSK PHARMA has posted a net profit of Rs 1 bn (up 26.0% YoY). Sales on the other hand came in at Rs 8 bn (up 17.3% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 324.1% (Quarterly Result Update)

Jan 31, 2019 | Updated on Jan 31, 2019

For the quarter ended December 2018, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 324.1% YoY). Sales on the other hand came in at Rs 21 bn (up 38.9% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 12.3% (Quarterly Result Update)

Nov 5, 2018 | Updated on Nov 5, 2018

For the quarter ended September 2018, TORRENT PHARMA has posted a net profit of Rs 2 bn (down 12.3% YoY). Sales on the other hand came in at Rs 19 bn (up 32.5% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

GSK PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 22.7% (Quarterly Result Update)

Oct 23, 2018 | Updated on Oct 23, 2018

For the quarter ended September 2018, GSK PHARMA has posted a net profit of Rs 1 bn (down 22.7% YoY). Sales on the other hand came in at Rs 8 bn (down 2.4% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (1QFY19); Net Profit Down 13.3% (Quarterly Result Update)

Aug 6, 2018 | Updated on Aug 6, 2018

For the quarter ended June 2018, TORRENT PHARMA has posted a net profit of Rs 2 bn (down 13.3% YoY). Sales on the other hand came in at Rs 19 bn (up 36.2% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

More Views on News

Most Popular

Are You Ready for the Big Nifty Move in the March Expiry?(Profit Hunter)

Mar 8, 2019

History suggests the Nifty could make a big move in March. Are you prepared to benefit from this opportunity?

Smallcaps Are Rallying and You Need to Make the Most of It Now(Profit Hunter)

Mar 7, 2019

Did you just miss the smallcap rally? Or is there still time to catch up? Read on for answers and more...

The One Sector to Bet on Today as India Grows into a 10 Trillion Dollar Economy(The 5 Minute Wrapup)

Mar 7, 2019

India's defence sector is suddenly under the spotlight. Can this sector ride along India's long-term growth story?

Is it the Right Time to Buy Mid and Small Caps Now?(The 5 Minute Wrapup)

Mar 6, 2019

Mid and Small Caps have underperformed large caps in the past year. Is the tide about to turn?

The Jet Airways Crisis in 6 Charts(Sector Info)

Mar 5, 2019

What happened to Jet Airways, once among top 3 airlines in India? Is it another Kingfisher in the making? Read on...

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

TORRENT PHARMA SHARE PRICE


Mar 18, 2019 (Close)

TRACK TORRENT PHARMA

  • Track your investment in TORRENT PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON TORRENT PHARMA

TORRENT PHARMA 5-YR ANALYSIS

COMPARE TORRENT PHARMA WITH

MARKET STATS